{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T13:25:06Z","timestamp":1793193906609,"version":"4.5.0"},"reference-count":23,"publisher":"American Society of Hematology","issue":"12","license":[{"start":{"date-parts":[[2024,4,9]],"date-time":"2024-04-09T00:00:00Z","timestamp":1712620800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,6,25]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>Hereditary hemorrhagic telangiectasia (HHT) is the second-most common inherited bleeding disorder (BD) worldwide and remains without approved therapies. HHT causes serious mucosal bleeding resulting in severe iron-deficiency anemia, major psychosocial complications, and visceral arteriovenous malformations in the brain, lung, and liver, which can cause life-threatening hemorrhagic complications. No study has examined the relative morbidity of HHT and von Willebrand disease (VWD), which is the most common inherited BD in women. We performed an observational cohort study of women with HHT or VWD, comparing a representative sample of 100 randomly selected women with HHT to 100 randomly selected age-matched women with VWD. In HHT vs VWD, recurrent epistaxis and gastrointestinal bleeding were more likely (odds ratio [OR], 32.73 [95% confidence interval, 13.81-71.80]; P\u00a0&amp;lt; .0001 and 5.69 [2.59-12.89]; P\u00a0&amp;lt; .0001) and heavy menstrual bleeding was less likely (OR, 0.32 [0.18-0.57]; P\u00a0&amp;lt; .0001). Iron-deficiency anemia was significantly more likely, and the lowest hemoglobin was significantly lower in HHT than in VWD. The odds of iron infusion dependence, requirement for red cell transfusion, and hemostatic surgical procedures were significantly higher\u201417-fold, threefold, and eightfold higher, respectively\u2014and hospital admissions to manage disease complications were both \u223c14 times more frequent in women with HHT vs those with VWD. In conclusion, much higher disease-related morbidity, mortality, and health care use were observed in women with HHT vs VWD, providing evidence that HHT may be the most clinically significant inherited BD in women. Given the vast gap in research funding for HHT compared with both hemophilia (a disease primarily of men) and VWD, these findings have significant implications for gender equity in hematology.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1182\/bloodadvances.2023011961","type":"journal-article","created":{"date-parts":[[2024,4,9]],"date-time":"2024-04-09T16:56:15Z","timestamp":1712681775000},"page":"3166-3172","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":27,"title":["Hereditary hemorrhagic telangiectasia may be the most morbid inherited bleeding disorder in women"],"prefix":"10.1182","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5365-4209","authenticated-orcid":false,"given":"Ellen","family":"Zhang","sequence":"first","affiliation":[{"name":"1Department of Medicine, Stanford University Medical Center, Palo Alto, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zain M.","family":"Virk","sequence":"additional","affiliation":[{"name":"2Department of Medicine, Vanderbilt University Medical Center, Nashville, TN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2637-0563","authenticated-orcid":false,"given":"Josanna","family":"Rodriguez-Lopez","sequence":"additional","affiliation":[{"name":"3Division of Pulmonary and Critical Care Medicine, Massachusetts General Hospital, Boston, MA"},{"name":"4Harvard Medical School, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6175-1383","authenticated-orcid":false,"given":"Hanny","family":"Al-Samkari","sequence":"additional","affiliation":[{"name":"4Harvard Medical School, Boston, MA"},{"name":"5Division of Hematology Oncology, Massachusetts General Hospital, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2024,6,14]]},"reference":[{"issue":"1","key":"2024062514354592500_bib1","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1111\/j.1538-7836.2009.03661.x","article-title":"The prevalence of symptomatic von Willebrand disease in primary care practice","volume":"8","author":"Bowman","year":"2010","journal-title":"J\u00a0Thromb Haemost"},{"issue":"7","key":"2024062514354592500_bib2","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1182\/blood.2020008739","article-title":"Hereditary hemorrhagic telangiectasia: systemic therapies, guidelines, and an evolving standard of care","volume":"137","author":"Al-Samkari","year":"2021","journal-title":"Blood"},{"issue":"7","key":"2024062514354592500_bib3","doi-asserted-by":"crossref","first-page":"e472","DOI":"10.1016\/S2352-3026(21)00164-2","article-title":"Giving hereditary hemorrhagic telangiectasia the attention it deserves","volume":"8","author":"Al-Samkari","year":"2021","journal-title":"Lancet Haematol"},{"key":"2024062514354592500_bib4","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.thromres.2017.03.003","article-title":"Depression and post-traumatic stress disorder in individuals with hereditary hemorrhagic telangiectasia: a cross-sectional survey","volume":"153","author":"Chaturvedi","year":"2017","journal-title":"Thromb Res"},{"issue":"9","key":"2024062514354592500_bib5","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1288\/00005537-199109000-00008","article-title":"The natural history of epistaxis in hereditary hemorrhagic telangiectasia","volume":"101","author":"Aassar","year":"1991","journal-title":"Laryngoscope"},{"issue":"9","key":"2024062514354592500_bib6","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.3324\/haematol.2018.193003","article-title":"Hereditary hemorrhagic telangiectasia: diagnosis and management from the hematologist's perspective","volume":"103","author":"Kritharis","year":"2018","journal-title":"Haematologica"},{"issue":"18","key":"2024062514354592500_bib7","doi-asserted-by":"crossref","first-page":"1886","DOI":"10.1212\/WNL.0000000000001538","article-title":"Complications and mortality in hereditary hemorrhagic telangiectasia: a population-based study","volume":"84","author":"Donaldson","year":"2015","journal-title":"Neurology"},{"issue":"8","key":"2024062514354592500_bib8","doi-asserted-by":"crossref","first-page":"2161","DOI":"10.3324\/haematol.2020.261859","article-title":"An international, multicenter study of intravenous bevacizumab for bleeding in hereditary hemorrhagic telangiectasia: the InHIBIT-Bleed study","volume":"106","author":"Al-Samkari","year":"2021","journal-title":"Haematologica"},{"issue":"1","key":"2024062514354592500_bib9","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1186\/s13023-020-1337-5","article-title":"Gender differences in hereditary hemorrhagic telangiectasia severity","volume":"15","author":"Mora-Lujan","year":"2020","journal-title":"Orphanet J Rare Dis"},{"issue":"9","key":"2024062514354592500_bib10","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1513\/AnnalsATS.201603-200OC","article-title":"High rates of bleeding complications among hospitalized patients with hereditary hemorrhagic telangiectasia in the United States","volume":"13","author":"Brinjikji","year":"2016","journal-title":"Ann Am Thorac Soc"},{"issue":"3","key":"2024062514354592500_bib11","doi-asserted-by":"crossref","first-page":"e161","DOI":"10.1016\/S2352-3026(21)00031-4","article-title":"Giving von Willebrand disease the attention it deserves","volume":"8","author":"The Lancet H","year":"2021","journal-title":"Lancet Haematol"},{"issue":"1","key":"2024062514354592500_bib12","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1182\/bloodadvances.2020003265","article-title":"ASH ISTH NHF WFH 2021 guidelines on the diagnosis of von Willebrand disease","volume":"5","author":"James","year":"2021","journal-title":"Blood Adv"},{"issue":"7","key":"2024062514354592500_bib13","doi-asserted-by":"crossref","first-page":"1954","DOI":"10.1182\/bloodadvances.2020003424","article-title":"Health care resource utilization and cost burden of hemophilia B in the United States","volume":"5","author":"Buckner","year":"2021","journal-title":"Blood Adv"},{"issue":"3","key":"2024062514354592500_bib14","doi-asserted-by":"crossref","first-page":"141","DOI":"10.5045\/br.2021.2020289","article-title":"Clinical analysis of hospitalized patients with hemophilia A: single-hemophilia treatment center experience in Korea over 10 years","volume":"56","author":"Kim","year":"2021","journal-title":"Blood Res"},{"key":"2024062514354592500_bib15","first-page":"189","article-title":"Von Willebrand disease epidemiology, burden of illness and management: a systematic review","volume":"14","author":"Du","year":"2023","journal-title":"J\u00a0Blood Med"},{"issue":"12","key":"2024062514354592500_bib16","doi-asserted-by":"crossref","first-page":"989","DOI":"10.7326\/M20-1443","article-title":"Second international guidelines for the diagnosis and management of hereditary hemorrhagic telangiectasia","volume":"173","author":"Faughnan","year":"2020","journal-title":"Ann Intern Med"},{"issue":"19","key":"2024062514354592500_bib17","doi-asserted-by":"crossref","first-page":"5843","DOI":"10.1182\/bloodadvances.2023010743","article-title":"Prevalence and risk factors for bleeding in hereditary hemorrhagic telangiectasia: a national inpatient sample study","volume":"7","author":"Zarka","year":"2023","journal-title":"Blood Adv"},{"issue":"5","key":"2024062514354592500_bib18","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1055\/s-0042-1743467","article-title":"Systemic antiangiogenic therapies for bleeding in hereditary hemorrhagic telangiectasia: a practical, evidence-based guide for clinicians","volume":"48","author":"Al-Samkari","year":"2022","journal-title":"Semin Thromb Hemost"},{"issue":"1","key":"2024062514354592500_bib19","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1186\/s13023-019-1239-6","article-title":"Systemic bevacizumab for high-output cardiac failure in hereditary hemorrhagic telangiectasia: an international survey of HHT centers","volume":"14","author":"Al-Samkari","year":"2019","journal-title":"Orphanet J Rare Dis"},{"issue":"2","key":"2024062514354592500_bib20","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1111\/joim.12832","article-title":"Systemic bevacizumab for the treatment of chronic bleeding in hereditary hemorrhagic telangiectasia","volume":"285","author":"Al-Samkari","year":"2019","journal-title":"J\u00a0Intern Med"},{"issue":"6","key":"2024062514354592500_bib21","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1111\/hae.14034","article-title":"An international survey to evaluate systemic bevacizumab for chronic bleeding in hereditary haemorrhagic telangiectasia","volume":"26","author":"Al-Samkari","year":"2020","journal-title":"Haemophilia"},{"issue":"1","key":"2024062514354592500_bib22","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1007\/s10456-021-09807-4","article-title":"Pazopanib for severe bleeding and transfusion-dependent anemia in hereditary hemorrhagic telangiectasia","volume":"25","author":"Parambil","year":"2022","journal-title":"Angiogenesis"},{"issue":"5","key":"2024062514354592500_bib23","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1111\/jth.15715","article-title":"A\u00a0precision medicine approach to hereditary hemorrhagic telangiectasia and complex vascular anomalies","volume":"20","author":"Al-Samkari","year":"2022","journal-title":"J\u00a0Thromb Haemost"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/8\/12\/3166\/2232083\/blooda_adv-2023-011961-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/8\/12\/3166\/2232083\/blooda_adv-2023-011961-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,25]],"date-time":"2024-06-25T10:36:27Z","timestamp":1719311787000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/8\/12\/3166\/515679\/Hereditary-hemorrhagic-telangiectasia-may-be-the"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,14]]},"references-count":23,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2024,6,25]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2023011961","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6,14]]}}}